Cargando…

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data

INTRODUCTION: In this literature review we evaluated the real-world clinical effectiveness of switching Japanese diabetic patients from their current insulin regimen to insulin degludec (IDeg). METHODS: Studies were identified from Japanese Diabetes Society (JDS) abstracts (2014–2015) and PubMed (20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaku, Kohei, Wolden, Michael Lyng, Hyllested-Winge, Jacob, Nørtoft, Emil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306124/ https://www.ncbi.nlm.nih.gov/pubmed/28091878 http://dx.doi.org/10.1007/s13300-017-0225-z

Ejemplares similares

Efficacy and safety of once‐daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26‐week, treat‐to‐target trial
por: Kadowaki, Takashi, et al.
Publicado: (2016)

Diabetes management and daily functioning burden of non‐severe hypoglycemia in Japanese people treated with insulin
por: Ohashi, Yasuo, et al.
Publicado: (2017)

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
por: Tentolouris, Nikolaos, et al.
Publicado: (2019)

Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study
por: Melzer Cohen, Cheli, et al.
Publicado: (2017)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial
por: Iwamoto, Yasuhiko, et al.
Publicado: (2013)

Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan
por: Kaku, Kohei, et al.
Publicado: (2015)

Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
por: Ikushima, Ippei, et al.
Publicado: (2015)

Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2018)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

NovoPen Echo(®) insulin delivery device
por: Hyllested-Winge, Jacob, et al.
Publicado: (2016)

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy
por: Langer, Jakob, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Long-Term Safety and Clinical Outcomes with Insulin Degludec/Insulin Aspart Treatment in Japanese Patients with Diabetes: A Real-World, Prospective, Observational Study
por: Katabami, Takuyuki, et al.
Publicado: (2021)

Safety and Clinical Outcomes of Insulin Degludec in Korean Patients with Diabetes in Real-World Practices: A Prospective, Observational Study
por: Lee, Byung Wan, et al.
Publicado: (2023)

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2019)

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials
por: Freemantle, N, et al.
Publicado: (2013)

Efficacy and Safety of Insulin Degludec for Hyperglycemia Management in Noncritical Hospitalized Patients with Diabetes: An Observational Study
por: Simioni, Natalino, et al.
Publicado: (2017)

Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population
por: Kochar, Inderpal Singh, et al.
Publicado: (2018)

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience
por: Oner, Hatice, et al.
Publicado: (2022)

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study
por: Kaku, Kohei, et al.
Publicado: (2018)

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes
por: Tibaldi, Joseph, et al.
Publicado: (2019)

One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)
por: Kesavadev, Jothydev, et al.
Publicado: (2022)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Effectiveness of Insulin Degludec in Thai Patients with Diabetes Mellitus: Real-World Evidence From a Specialized Diabetes Center
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2021)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
por: Mehta, Roopa, et al.
Publicado: (2020)

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials
por: Freemantle, N, et al.
Publicado: (2013)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
por: Komatsu, Mitsuhisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e8mikril94j5qp4s8ss17ab9jb